Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 72205-183

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 72205-183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bortezomib-carton-label (Bortezomib Carton Label)

The packaging label for Bortezomib for Injection 3.5 mg/Vial, a lyophilized powder for intravenous or subcutaneous use, single-dose vial, labeled by Novadoz Pharmaceuticals LLC. The label includes storage instructions, reconstitution information, manufacturer details (MSN Laboratories, India), and warnings about its cytotoxic nature. The label also provides barcode, NDC 72205-183-01, and contact information.*

FDA Label Image

Fig-1 (Bortezomib Fig 1)

A Kaplan-Meier survival curve showing the percentage of patients over time (in months) for two groups labeled B-MP and MP. The graph includes patient counts at risk over multiple time points and a reported p-value of 0.000002 from a log-rank test, indicating a statistical comparison between groups.*

FDA Label Image

Fig-2 (Bortezomib Fig 2)

A Kaplan-Meier survival curve chart displaying the percentage of patients over time in months. Two groups are compared: B-MP (dotted line) and MP (solid line). The chart includes the number of patients at risk at various time points and notes a p-value less than 0.05 from a log-rank test, indicating a statistical comparison between groups.*

FDA Label Image

Bortezomib-fig-5 (Bortezomib Fig 5)

A Kaplan-Meier survival curve chart showing the percentage of patients over time in months for two treatment groups, BR-CAP and R-CHOP. The y-axis represents the percentage of patients, and the x-axis shows time in months up to 66. The chart includes a table of subjects at risk for both groups at various time points, with a log rank test p-value less than 0.001 indicating statistical significance.*

FDA Label Image

Bortezomib-fig-6 (Bortezomib Fig 6)

A Kaplan-Meier survival curve comparing two treatment groups, BR-CAP (solid line) and R-CHOP (dashed line), showing the percentage of subjects alive over time in months from randomization. The graph includes a hazard ratio with 95% confidence interval (0.66 [0.51, 0.85]) and the number of subjects at risk for each group at various time points below the x-axis.*

FDA Label Image

Fig-3 (Bortezomib Figure 3)

A Kaplan-Meier survival plot comparing the proportion of patients over time (days) between two treatments: Bortezomib and Dexamethasone. The y-axis shows the proportion of patients, and the x-axis shows time in days up to 480. The graph includes patient counts at specified time points for each treatment group and notes a p-value from a log-rank test.*

FDA Label Image

Fig-4 (Bortezomib Figure 4)

A survival curve chart comparing the proportion of patients over time (days) between two treatments: Bortezomib and Dexamethasone. The y-axis represents the proportion of patients, and the x-axis represents time in days up to 450 days. The chart shows patient count at specific time points and a noted p-value less than 0.05 from a log-rank test, indicating statistical comparison between the two treatments.*

FDA Label Image

Bortezomib-intravenous-sticker (Bortezomib Intravenous Sticker)

Label for Bortezomib for Injection 3.5 mg/3.5 mL lyophilized powder for solution, specifying intravenous injection only. Instructions indicate adding 3.5 mL of 0.9% sodium chloride to achieve a final concentration of 1 mg/mL. The label also directs placing stickers marked 'Intravenous Bortezomib' on both vial and syringe, with a note to see package insert for full instructions.*

FDA Label Image

Structure (Bortezomib Structure)

Chemical structure of Bortezomib, showing its molecular arrangement with characteristic rings and functional groups as a peptide boronic acid derivative.*

FDA Label Image

Bortezomib-subcutaneous-sticker (Bortezomib Subcutaneous Sticker)

Label for Bortezomib for Injection, highlighting subcutaneous injection only. It instructs to add 1.4 mL of 0.9% sodium chloride to achieve a final concentration of 2.5 mg/mL. The label includes directions to place stickers on the vial and syringe for subcutaneous Bortezomib. Manufacturer or labeler is not shown in the image.*

FDA Label Image

Bortezomib-vial-label (Bortezomib Vial Label)

Bortezomib for Injection 3.5 mg/vial lyophilized powder single-dose vial label. Intended for intravenous or subcutaneous use. Distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ, and manufactured by MSN Laboratories Private Limited, India. The label includes storage instructions and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.